Haemonetics Corporation
HAE | NYSE
$120.91
+$1.26 (+1.05%)
Nov 2, 2026, 12:29 PM ET · Market open
Company Profile
Haemonetics Corporation is a healthcare enterprise dedicated to providing medical products and comprehensive solutions, structured into three main business areas: Plasma, Blood Center, and Hospital. In its Plasma segment, the company develops automated plasma collection systems, exemplified by the NexSys PCS and PCS2 devices, along with necessary disposables and intravenous solutions. It also offers integrated information technology platforms and the NexLynk DMS donor management system to help plasma customers efficiently manage their donors, operations, and supply chains. The Blood Center division provides advanced automated blood component and manual whole blood collection technologies. This includes MCS brand apheresis equipment for selectively collecting blood components, as well as disposable kits for whole blood collection and storage. Its software offerings feature the SafeTrace Tx blood bank information system and BloodTrack, a sophisticated suite of blood management software and hardware designed to enhance hospital blood bank functionalities and facilitate bedside transfusions. For the Hospital sector, Haemonetics offers hemostasis analyzer systems like TEG, ClotPro, and HAS, which deliver crucial assessments of a patient's overall clotting ability. The TEG Manager software links these analyzers throughout a facility, enabling clinicians to remotely access active and past test results to inform treatment decisions. Additionally, the Cell Saver Elite+ system supports autologous blood recovery across a wide range of surgical procedures, including cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological operations. The company distributes its products and solutions through its own direct sales teams, independent distributors, and sales representatives. Haemonetics Corporation was established in 1971 and is based in Boston, Massachusetts.
Key Executives
| Name | Position |
|---|---|
| Christopher A. Simon | Chief Executive Officer, President & Director |
| Frank W. Chan | Executive Vice President & Chief Operating Officer |
| James C. D'Arecca | Chief Financial Officer, Executive Vice President & Financial Officer |
| Farris Maryanne Maunsell | Vice President, Chief Accounting Officer & Principal Accounting Officer |
| Josh Gitelson | Senior Director of Global Communications |
| Laurie A. Miller | Senior Vice President & Chief Human Resources Officer |
| Michelle L. Basil | Executive Vice President, General Counsel & Secretary |
| Olga Guyette | VP of IR & Treasury |
| Rajeev Varma | Senior Vice President of Strategy & Corporate Development |
| Roy Galvin | Executive Vice President & Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 18, 2026 | 8-K | Current Report |
| Aug 12, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 06, 2026 | S-8 | Filing |
| Aug 06, 2026 | 10-Q | Quarterly Report |
| Aug 06, 2026 | 8-K | Current Report |
| Jul 28, 2026 | 4 | Filing |
| Jul 28, 2026 | 4 | Filing |
| Jul 28, 2026 | 4 | Filing |
| Jul 28, 2026 | 4 | Filing |
| Jul 28, 2026 | 4 | Filing |
Haemonetics Corporation
| Country | United States |
| IPO Date | May 10, 1991 |
| Industry | Medical - Devices |
| Sector | Healthcare |
| Employees | 3,009 |
| CEO | Christopher A. Simon |
Contact Details
125 Summer Street Boston,
Massachusetts 02110 United States
Stock Details
| Ticker Symbol | HAE |
| Exchange | NYSE |
| Fiscal Year | May - April |
| Reporting Currency | USD |
| CIK Code | 0000313143 |
| CUSIP Number | 405024100 |
| ISIN Number | US4050241003 |
| SIC Code | 3841 |
Recent News
- 6 days ago / zacks.comAll You Need to Know About Haemonetics (HAE) Rating Upgrade to Buy
- 12 days ago / globenewswire.comBioCryst Announces U.S. FDA Approval of ORLADEYO® 150 mg Oral Pellets for Adults and Adolescents with HAE
- 14 days ago / prnewswire.comHaemonetics Announces FDA Approval of PerQseal® Elite Vascular Closure System
- 17 days ago / zacks.comHaemonetics Gains 149.3% in a Year: What's Driving the Rally?
- 20 days ago / zacks.comWhy Haemonetics (HAE) is a Top Momentum Stock for the Long-Term
- 24 days ago / zacks.comStrength Seen in Haemonetics (HAE): Can Its 17.5% Jump Turn into More Strength?
- 25 days ago / gurufocus.comIs Haemonetics Corp (HAE) Overvalued After 17.5% Rally? GF Value Says Overvalued
- 25 days ago / globenewswire.comPhase 3 Study Results Highlighting Deucrictibant's Rapid and Sustained Efficacy in Treating HAE Attacks Published in The Lancet
- 25 days ago / proactiveinvestors.comHaemonetics shares jump as CSL sets 2027 rollout of plasma devices
- 25 days ago / barrons.comHaemonetics Stock Surges as Plasma Deal Opens Door to More Revenue
Add to Watchlist
Select watchlists to add or remove HAE